The DEA rescheduling hearing came back from its Fourth-of-July recess and kept doing the thing that still surprises people: the government is building the record for moving marijuana to Schedule III. The two-week administrative proceeding recessed July 3, reconvened July 6, and runs no later than July 15. Week one opened with an FDA scientist; week two moved to clinical medicine.
Here is what a searcher needs up front: after the FDA witness, the government lined up Dr. Corey Burchman, a New Hampshire physician of more than 30 years, to testify as a medical expert in pain management with significant clinical experience using medical marijuana. That is the “currently accepted medical use” case being made witness by witness.
Why the DEA rescheduling hearing is so lopsided
The structural oddity from week one holds: the DEA designated just seven parties to participate, and every one of them opposes rescheduling. Advocacy groups like NORML keep hammering that the industry itself has no seat — the people with billions at stake get to watch, not testify (a point laid out in this in-hearing op-ed). So the record is being built by the government’s proponents and cross-examined only by prohibitionists.
Keep your eye on the ball anyway: the DEA is the proponent here. For 50 years this agency fought rescheduling; now its lawyers are stacking the administrative record with an FDA scientist and a three-decade pain doctor while the opponents attack the test rather than the science.
What it means for operators
This is the record a reviewing court eventually reads. Medical-use testimony piling up in Arlington is exactly the evidence that survives appeal — and Schedule III is what finally frees plant-touching businesses from 280E and its punishing tax math. If you run a medical program, the direction of travel is toward standardized, defensible product, a theme we covered when we broke down what Schedule III means for pharmaceutical-grade MMJ. It also connects to this week’s reminder that seniors are now the fastest-growing medical-cannabis patients — the exact population the CAMU record is about. For the deeper 280E and interstate mechanics, Cannabis Industry Lawyer tracks it for operators.
How the DEA rescheduling hearing fits the bigger fight
Remember there are two tracks running at once. The administrative DEA rescheduling hearing is building the factual record on whether cannabis has a currently accepted medical use. Separately, opponents are in the D.C. Circuit trying to freeze the whole thing, and the Justice Department is fighting them there too. The hearing feeds the court case — a reviewing judge reads the record the ALJ compiles. That’s why every day of pro-Schedule-III testimony matters even though the room is stacked with opponents.
The clock is real: the proceeding is scheduled to wrap no later than July 15, after which the administrative law judge issues a recommended decision. That recommendation isn’t the final word — the DEA administrator ultimately decides — but it shapes everything downstream, including the inevitable appeals.
DEA rescheduling hearing FAQ
When does the DEA rescheduling hearing end? It reconvened July 6 after the July 4 recess and is scheduled to conclude no later than July 15, 2026.
Does Schedule III legalize marijuana? No. It moves cannabis from Schedule I to III, which chiefly ends the 280E tax penalty and eases research — it does not create a legal recreational market or federal legalization.
Watch the full episode
Watch the full Cannabis Legalization News episode on YouTube →
